Search filters
Filters
Clear All

Phase

  • 183
  • 156
  • 2
  • 194
  • 1
  • 148
  • 17
  • 396
  • 1237
  • 588
  • 29
  • 49
  • 3
  • 1162
  • 1237
  • 6
  • 3
  • 1240

Found 1243 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 07718: INSPIRE: A Multicenter Randomized Controlled Trial integrating health informatics in a scalable

99 years or below
All genders
We would like to rely on the Fred Hutchinson Cancer Research Center (FHCRC) as IRB of record for this study. We are doing this study to examine ways to improve the health of long-term survivors of bone marrow or blood stem cell transplant. We want to know if an online …
Learn More

UPCC 10122 A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1

99 years or below
All genders
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Learn More

UPCC 06918:A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors

99 years or below
All genders
We are requesting to rely on WIRB as IRB of record for this study. This Study has 2 parts. The purpose of the Part 1 is to try to find the best dose of INCB081776 alone for patients who have advanced cancer. The purpose of Part 2 is to find …
Learn More

UPCC 04223: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours

99 years or below
All genders
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder for whom previous treatment was not successful or no treatment exists, to find out whether a medicine called BI 907828 helps. BI 907828 is a so-called MDM2 inhibitor that is being developed to …
Learn More
Evaluating Using Rescue Therapies for CAR T cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome

Evaluating Using Rescue Therapies for CAR T cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome

18 years - 99 years
All genders
Interventional
This research study is being conducted to evaluate experimental rescue therapies for the treatment of cytokine release syndrome (CRS) and CAR T cell related HLH-like syndrome (CRHLS). These are both life-threatening side effects which can occur in some patients after infusion with a CAR T cell product. This consent allows …
Learn More

Study of Direct Brain Recording and Stimulation for Memory Enhancement (Data Coordinating Center Protocol) (PRIME)

18 years - 99 years
All genders
Interventional
The purpose of this research study is to learn more about how the brain stores and retrieves different kinds of information from memory, and whether brain stimulation can improve the storage and retrieval of memories. We are enrolling subjects with drug-resistant epilepsy, who are expected to undergo placement of electrodes …
Learn More

Study to Evaluate Study Drug XmAb 20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)

18 years - 99 years
All genders
The primary purposes of this research study are to determine the safety and tolerability of dose levels of the investigational drug, XmAb20717, and if XmAb20717 works in treating advanced solid tumors that have progressed after treatment with standard cancer therapies or solid tumors for which there are no appropriate therapies …
Learn More

NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-zzxf (PHESGO) in HER2 Positive Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

99 years or below
All genders
This Study tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. We would like to rely on CIRB as the IRB of record for …
Learn More

UPCC 03423: A Phase 1b/2a Open-label Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis and Anemia

99 years or below
All genders
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis and anemia. We would like to rely on Advarra as the IRB of record for this study.
Learn More

UPCC 16122 A Phase II Multicentre Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Patients with BRCA Mutations and Early Stage HER2-Negative Breast Cancer (OlympiaN)

99 years or below
All genders
This study to learn more about olaparib and olaparib plus durvalumab combination therapy and also to better understand the studied disease, breast cancer, and associated health problems.
Learn More
1161 - 1170 of 1243